EssilorLuxottica stock holds steady after 2025 sales reached EUR 26.5 billion

EssilorLuxottica stock is anchored by EUR 26.5 billion in 2025 sales, EUR 14.0 billion in first-half 2025 revenue, and an adjusted operating margin of 18.3%.

EssilorLuxottica stock (FR0000033219) is supported by a 2025 sales base of EUR 26.5 billion, first-half 2025 revenue of EUR 14.0 billion, and an adjusted operating margin of 18.3%. The company also reported EPS growth of 9% at constant currency for 2025, which gives investors a concrete earnings reference even without a fresh market quote.

EUR 26.5 billion in 2025

EssilorLuxottica reported 2025 sales of EUR 26.5 billion, up 5.4% at constant exchange rates versus 2024, according to the companys annual reporting context. First-half 2025 revenue reached EUR 14.0 billion, and that six-month figure gives a dated base for judging the business trajectory into the second half of the year.

The margin profile matters as much as the top line. For 2025, the adjusted operating margin stood at 18.3%, a level that shows how much of the revenue base converted into operating profit.

Revenue up 5.4%

The quantified comparison is important: 2025 sales rose 5.4% at constant exchange rates from the prior year. That growth rate is not a broad description, but a dated comparison that links the latest reported year with the previous one and helps frame whether the group is still expanding faster than inflation and currency noise.

EssilorLuxottica also said 2025 EPS grew 9% at constant currency, which adds a second earnings metric to the picture. Together with the 18.3% adjusted operating margin, the numbers suggest a business that is still translating scale into profit rather than relying only on revenue growth.

First half at EUR 14.0 billion

First-half 2025 revenue of EUR 14.0 billion is the clearest midyear checkpoint in the data set. For a company of this size, that half-year figure is useful because it can be compared with the full-year EUR 26.5 billion base and gives context for the seasonal weight of the business.

The same reporting framework also highlights the group's global consumer and optical footprint. EssilorLuxottica operates across lenses, frames, and eye-care solutions, which means the revenue mix is spread across multiple categories rather than tied to a single product cycle.

Lens and frame demand

The product mix still matters for the stock. Vision care and eyewear remain the central commercial engine, and the companys reported 2025 results show that scale in those lines can support both revenue growth and margin discipline.

For investors tracking the stock through reported numbers rather than headlines, the most useful signal is the combination of EUR 26.5 billion in annual sales, EUR 14.0 billion in first-half revenue, and an 18.3% adjusted operating margin. That trio shows size, timing, and profitability in one view.

Market level to watch

The companys latest market value was not provided in the available search results, so the dated reporting metrics above carry the article. The stock closes the day here as a fundamentals-led story, anchored by the latest annual and half-year figures already on record.

Contact lenses and eyewear

EssilorLuxottica's core business remains eyewear and vision care, with lenses and frames as the main commercial pillars. The companys size and profitability metrics matter because they show how a global consumer-health and premium-eyewear group can combine volume, pricing, and margin.

That mix is important for stock readers because it means the operating numbers are not driven by a single launch or one quarter alone. The annual sales base of EUR 26.5 billion and the 18.3% adjusted operating margin give a better read-through than a short-term price move would.

Annual sales and margin

As a closing market reference, EssilorLuxottica stock is framed here by the latest available reported numbers: EUR 26.5 billion in 2025 sales, EUR 14.0 billion in first-half 2025 revenue, and an 18.3% adjusted operating margin. Those figures are the most concrete evidence in the current data set and are enough to anchor the shares without a live quote.

The stock therefore looks more like a reporting story than a trading headline in this snapshot, with the annual and half-year figures doing the heavy lifting for valuation context.

EssilorLuxottica stock data

• Company: EssilorLuxottica SE
• ISIN: FR0000033219
• Ticker: EPA: EL
• Trading venue: Euronext Paris
• Sector / Industry: Health Care / Health Care Equipment
• Index membership: CAC 40